No products in the cart.
Pre-made Lenzilumab benchmark antibody ( Whole mAb, anti-CSF2 therapeutic antibody, Anti-CSF/GMCSF Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-303
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lenzilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lenzilumab (INN; development code KB003)[1] is a humanized monoclonal antibody (class IgG1 kappa)[2] that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF).
| Products Name (INN Index) | Pre-Made Lenzilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody |
|---|---|
| INN Name | Lenzilumab |
| Target | CSF2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Humanigen,KaloBios Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | COVID-19,Cytokine release syndrome,B-cell lymphoma,Drug hypersensitivity,Precursor cell lymphoblastic leukaemia-lymphoma,Graft-versus-host disease |
| Conditions Discontinued | Asthma,Rheumatoid arthritis,Chronic myelomonocytic leukaemia,Solid tumours |
| Development Tech | Humaneering Technology |
| Previous Name | NA |
| Gm Offical Target Name | CSF2 |
| Package |
Previous slide
Next slide
